Glempa M 5/1000mg Tablet contains two active ingredients: Empagliflozin & Metformin hydrochloride (HCI). Empagliflozin belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, while metformin HCI is a biguanide antidiabetic medication. This combination medication is prescribed for the treatment of type 2 diabetes mellitus.
- Empagliflozin: An SGLT2 inhibitor, empagliflozin helps reduce blood sugar levels by inhibiting the reabsorption of glucose in the kidneys, leading to increased urinary excretion of glucose.
- Metformin HCI: This is a biguanide antidiabetic drug that lowers blood sugar levels by decreasing hepatic glucose production, reducing intestinal absorption of glucose, and improving insulin sensitivity.
Glempa M Tablet is indicated for managing type 2 diabetes mellitus in adults. It aids in improving glycemic control by lowering blood sugar levels through different mechanisms: empagliflozin promotes urinary glucose excretion, while metformin HCI reduces hepatic glucose production and enhances insulin sensitivity.
Mechanism of Action:
- Empagliflozin: Inhibits sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which reduces glucose reabsorption from the tubular lumen and increases urinary glucose excretion.
- Metformin HCI: Decreases hepatic glucose production, inhibits gluconeogenesis, reduces intestinal absorption of glucose, and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.
Glempa M Tablet is usually taken orally with meals as directed by a healthcare professional. The dosage may vary depending on individual response and other factors. Patients should follow the dosage instructions provided by their healthcare provider.
Common side effects of Glempa M Tablet may include:
- Hypoglycemia (low blood sugar)
- Genital yeast infections
- Urinary tract infections
- Increased urination
- Abdominal pain
Before using Glempa M Tablet, patients should consider the following precautions:
- Inform healthcare providers of any known allergies to empagliflozin, metformin HCI, or other medications.
- Regularly monitor blood sugar levels, especially during initial treatment or dosage adjustments.
- Use caution in patients with kidney problems, dehydration, or hypotension.
- Avoid excessive alcohol consumption, as it may increase the risk of lactic acidosis.
- Inform healthcare providers of any other medications, supplements, or herbal products being taken, as they may interact with empagliflozin or metformin HCI.